Titan Pharmaceuticals, Inc.
TTNP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.17 | -0.34 | 0.05 | -0.15 |
| FCF Yield | -11.33% | -15.20% | -26.87% | -17.27% |
| EV / EBITDA | -5.90 | -2.54 | -2.40 | -0.15 |
| Quality | ||||
| ROIC | -39.14% | -23.57% | -28.45% | -27.30% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 0.94 | 0.99 | 1.54 | 0.64 |
| Growth | ||||
| Revenue 3-Year CAGR | -59.81% | -59.81% | -67.92% | -70.69% |
| Free Cash Flow Growth | -11.62% | 21.57% | -71.34% | 26.98% |
| Safety | ||||
| Net Debt / EBITDA | 2.43 | 4.27 | 3.64 | 4.25 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 558.00 |